Published in Biol Psychol on February 23, 2006
Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend (2009) 2.03
Factors related to seizure in tramadol poisoning and its blood concentration. J Med Toxicol (2011) 1.87
Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend (2012) 1.85
The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend (2008) 1.60
Tramadol use in premature ejaculation: daily versus sporadic treatment. Indian J Psychol Med (2013) 1.09
Modest opioid withdrawal suppression efficacy of oral tramadol in humans. Psychopharmacology (Berl) (2007) 1.06
Conditional deletion of the NMDA-NR1 receptor subunit gene in the central nucleus of the amygdala inhibits naloxone-induced conditioned place aversion in morphine-dependent mice. Exp Neurol (2008) 0.98
The role of tramadol in current treatment strategies for musculoskeletal pain. Ther Clin Risk Manag (2007) 0.98
Discriminative stimulus effects of tramadol in humans. J Pharmacol Exp Ther (2011) 0.97
Changes in the rewarding effects induced by tramadol and its active metabolite M1 after sciatic nerve injury in mice. Psychopharmacology (Berl) (2008) 0.93
The prescription opioid, oxycodone, does not alter behavioral measures of impulsivity in healthy volunteers. Pharmacol Biochem Behav (2009) 0.93
Physical dependence potential of daily tramadol dosing in humans. Psychopharmacology (Berl) (2010) 0.90
Psychopharmacological effects of oxycodone in healthy volunteers: roles of alcohol-drinking status and sex. Drug Alcohol Depend (2009) 0.88
Abuse potential of carbohydrates for overweight carbohydrate cravers. Psychopharmacology (Berl) (2008) 0.87
Effects of repeated tramadol and morphine administration on psychomotor and cognitive performance in opioid-dependent volunteers. Drug Alcohol Depend (2010) 0.87
Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment. Psychopharmacology (Berl) (2012) 0.85
Worldwide research productivity on tramadol: a bibliometric analysis. Springerplus (2016) 0.84
Abuse liability and reinforcing efficacy of oral tramadol in humans. Drug Alcohol Depend (2012) 0.83
Tapentadol extended-release for treatment of chronic pain: a review. J Pain Res (2011) 0.82
Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial. Drug Alcohol Depend (2013) 0.80
Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users. Psychopharmacology (Berl) (2013) 0.77
The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users. Pharmacol Biochem Behav (2014) 0.75
Tramadol is an opioid. J Med Toxicol (2008) 0.75
A randomized, double-blind, placebo-controlled, crossover trial of "on-demand" tramadol for treatment of premature ejaculation. Urol Ann (2015) 0.75
College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend (2003) 6.80
Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology (Berl) (2000) 4.95
Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol (1998) 3.70
Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther (1992) 3.58
Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry (1978) 3.33
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry (1998) 3.27
A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend (1999) 1.78
Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther (1993) 1.71
Tramadol dependence with no history of substance abuse. Am J Psychiatry (2001) 1.62
Methods for evaluating addiction liability. (A) "Attitude" of opiate addicts toward opiate-like drugs. (B) a short-term "direct" addiction test. J Pharmacol Exp Ther (1961) 1.54
Development of scales based on patterns of drug effects, using the addiction Research Center Inventory (ARCI). Psychol Rep (1966) 1.48
Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol (2000) 1.47
Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J Pharmacol Exp Ther (1996) 1.41
Evaluation of nalbuphine for abuse potential. Clin Pharmacol Ther (1972) 1.38
Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro. Br J Pharmacol (1993) 1.34
[Biotransformation of tramadol in man and animal (author's transl)]. Arzneimittelforschung (1981) 1.30
Buprenorphine suppresses heroin use by heroin addicts. Science (1980) 1.27
Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend (1991) 1.23
Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. Br J Pharmacol (1992) 1.21
Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend (2003) 1.15
Prediction of abuse liability of drugs using IV self-administration by rats. Psychopharmacology (Berl) (1984) 1.15
Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine. J Pharmacol Exp Ther (2000) 1.14
Subjective and discriminative effects of drugs. Behav Pharmacol (1991) 1.02
[Pharmacological studies on analgesia, dependence on and tolerance of tramadol, a potent analgetic drug (author's transl)]. Arzneimittelforschung (1978) 1.01
Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth (1997) 0.99
Tramadol post-marketing surveillance in health care professionals. Drug Alcohol Depend (2002) 0.99
Postoperative patient-controlled analgesia with tramadol: analgesic efficacy and minimum effective concentrations. Clin J Pain (1990) 0.98
Opioid efficacy in a C6 glioma cell line stably expressing the delta opioid receptor. J Pharmacol Exp Ther (1997) 0.97
Comparison of potency and duration of action of nalmefene and naloxone. Anesth Analg (1994) 0.96
A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises. Soc Sci Med (2002) 0.95
Clinical investigation on the development of dependence during oral therapy with tramadol. Arzneimittelforschung (1985) 0.94
Acute effects of tramadol in methadone-maintained volunteers. Drugs (1994) 0.94
Acute abstinence syndrome following abrupt cessation of long-term use of tramadol (Ultram): a case study. Eur J Pain (2000) 0.94
Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys. Eur J Pharmacol (2000) 0.94
Antinociception, tolerance, and physical dependence comparison between morphine and tramadol. Pharmacol Biochem Behav (1998) 0.94
Effects of opiates and opiate antagonists on the Straub tail reaction in mice. Br J Pharmacol (1969) 0.93
An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride). Drug Alcohol Depend (2003) 0.92
Drug dependence potential of 1-(m-methoxyphenyl)-2-dimethylaminomethyl)-cyclohexan-1-ol hydrochloride (tramadol) tested in monkeys. Arzneimittelforschung (1978) 0.92
Abuse of combinations of carisoprodol and tramadol. South Med J (2001) 0.90
Withdrawal syndrome from tramadol hydrochloride. Am J Emerg Med (2003) 0.90
Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS Drugs (2002) 0.88
Methadone detoxification of tramadol dependence. J Subst Abuse Treat (2000) 0.88
Studies on dependence on tramadol in rats. Arzneimittelforschung (1978) 0.88
Dependence on tramadol. Clin Investig (1993) 0.88
Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. J Pharmacol Exp Ther (1996) 0.87
Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug Alcohol Depend (1997) 0.87
Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans. Drug Alcohol Depend (2000) 0.86
Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O-desmethyltramadol, in rats. J Pharmacol Exp Ther (2000) 0.85
Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. J Clin Psychopharmacol (2002) 0.84
D-16949 (anpirtoline): a novel serotonergic (5-HT1B) psychotherapeutic agent assessed by its discriminative effects in the rat. J Pharmacol Exp Ther (1992) 0.83
In vivo microdialysis and conditioned place preference studies in rats are consistent with abuse potential of tramadol. Synapse (2002) 0.83
Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug Alcohol Depend (2003) 0.83
Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: a preliminary study. Am J Addict (2003) 0.82
Influence of tramadol on morphine discriminative behavior in rats. Acta Pharmacol Sin (2000) 0.82
Opiate withdrawal after tramadol and patient-controlled analgesia. Anaesthesia (2000) 0.80
The effect of narcotics and narcotic antagonists on the tail-flick response in spinal mice. J Pharm Pharmacol (1969) 0.79
Comparative physical dependence studies in rats with flupirtine and opiate receptor stimulating analgesics. Postgrad Med J (1987) 0.79
Pharmacological mechanisms of action of flupirtine: a novel, centrally acting, nonopioid analgesic evaluated by its discriminative effects in the rat. J Pharmacol Exp Ther (1988) 0.79
Lack of sensitization during place conditioning in rats is consistent with the low abuse potential of tramadol. Neurosci Lett (2002) 0.78
Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification. Clin Pharmacol Ther (1985) 0.77
A simple, reliable method for predicting the physical dependence liability of narcotic antagonist analgesics in the rat. Pharmacol Biochem Behav (1981) 0.76
Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology (Berl) (2006) 4.23
Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction (2011) 3.42
Real-time electronic diary reports of cue exposure and mood in the hours before cocaine and heroin craving and use. Arch Gen Psychiatry (2009) 2.95
Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend (2005) 2.26
Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving. Neuropsychopharmacology (2006) 2.15
Cognitive-behavioral therapy plus contingency management for cocaine use: findings during treatment and across 12-month follow-up. Psychol Addict Behav (2003) 1.94
Tobacco, cocaine, and heroin: Craving and use during daily life. Addict Behav (2009) 1.56
Transferring methadone-stabilized pregnant patients to buprenorphine using an immediate release morphine transition: an open-label exploratory study. Am J Addict (2006) 1.47
Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther (2004) 1.46
Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat (2009) 1.44
Incubation of cue-induced cigarette craving during abstinence in human smokers. Biol Psychiatry (2011) 1.44
The reinstatement model and relapse prevention: a clinical perspective. Psychopharmacology (Berl) (2003) 1.43
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) (2007) 1.32
Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addict Behav (2005) 1.31
Daily life hour by hour, with and without cocaine: an ecological momentary assessment study. Psychopharmacology (Berl) (2010) 1.21
Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. Drug Alcohol Depend (2005) 1.13
Are We There Yet? Feasibility of Continuous Stress Assessment via Wireless Physiological Sensors. ACM BCB (2015) 1.12
Clonidine blocks stress-induced craving in cocaine users. Psychopharmacology (Berl) (2011) 1.12
Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug Alcohol Depend (2008) 1.11
Heroin and cocaine craving and use during treatment: measurement validation and potential relationships. J Subst Abuse Treat (2006) 1.08
Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug Alcohol Depend (2003) 1.08
Randomized trial of prize-based reinforcement density for simultaneous abstinence from cocaine and heroin. J Consult Clin Psychol (2007) 1.06
Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatients. Biol Psychiatry (2010) 1.05
The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J (2006) 1.01
Marriage and relationship closeness as predictors of cocaine and heroin use. Addict Behav (2008) 0.96
Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain (2012) 0.95
A dose response study of cognitive behavioral therapy in cocaine abusers. J Subst Abuse Treat (2002) 0.95
Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course. Drug Alcohol Depend (2011) 0.95
Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. J Subst Abuse Treat (2007) 0.94
Contingency management reduces injection-related HIV risk behaviors in heroin and cocaine using outpatients. Addict Behav (2007) 0.94
Long-term opioid therapy, aberrant behaviors, and substance misuse: comparison of patients treated by resident and attending physicians in a general medical clinic. J Opioid Manag (2012) 0.93
Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients. Addict Behav (2006) 0.93
Psychosocial functioning and cocaine use during treatment: strength of relationship depends on type of urine-testing method. Drug Alcohol Depend (2007) 0.90
Adverse events among patients in a behavioral treatment trial for heroin and cocaine dependence: effects of age, race, and gender. Drug Alcohol Depend (2005) 0.90
Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans. Exp Clin Psychopharmacol (2006) 0.87
Effect of reinforcement probability and prize size on cocaine and heroin abstinence in prize-based contingency management. J Appl Behav Anal (2008) 0.87
Effects of high-dose intravenous buprenorphine in experienced opioid abusers. J Clin Psychopharmacol (2004) 0.86
Sex differences in cocaine/heroin users: drug-use triggers and craving in daily life. Drug Alcohol Depend (2013) 0.85
Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. J Addict Med (2008) 0.85
Self-report of illicit benzodiazepine use on the Addiction Severity Index predicts treatment outcome. Drug Alcohol Depend (2008) 0.85
Buprenorphine and norbuprenorphine in hair of pregnant women and their infants after controlled buprenorphine administration. Clin Chem (2007) 0.85
Influence of psychotherapy attendance on buprenorphine treatment outcome. J Subst Abuse Treat (2005) 0.84
A randomized investigation of methadone doses at or over 100 mg/day, combined with contingency management. Drug Alcohol Depend (2012) 0.84
Hemodynamic and cognitive effects of lofexidine and methadone coadministration: a pilot study. Pharmacotherapy (2007) 0.83
Do noncontingent vouchers increase drug use? Exp Clin Psychopharmacol (2003) 0.83
Methadone treatment induces attenuation of cerebrovascular deficits associated with the prolonged abuse of cocaine and heroin. Neuropsychopharmacology (2002) 0.83
A focus-group study on spirituality and substance-user treatment. Subst Use Misuse (2010) 0.83
Spiritual/Religious experiences and in-treatment outcome in an inner-city program for heroin and cocaine dependence. J Psychoactive Drugs (2007) 0.82
Electrocardiographic effects of lofexidine and methadone coadministration: secondary findings from a safety study. Pharmacotherapy (2009) 0.82
TGI Monday?: drug-dependent outpatients report lower stress and more happiness at work than elsewhere. Am J Addict (2012) 0.82
Automation in an addiction treatment research clinic: computerised contingency management, ecological momentary assessment and a protocol workflow system. Drug Alcohol Rev (2009) 0.81
Smartphone Delivery of Mobile HIV Risk Reduction Education. AIDS Res Treat (2013) 0.80
Toxicologic aspects of heroin substitution treatment. Ther Drug Monit (2002) 0.80
QT interval increased after single dose of lofexidine. BMJ (2004) 0.80
A resident clerkship that combines inpatient and outpatient training in substance abuse and HIV care. Subst Abus (2004) 0.80
A high-level specification for adaptive ecological momentary assessment: real-time assessment of drug craving, use and abstinence. AMIA Annu Symp Proc (2005) 0.80
Determination of total and free concentrations of the enantiomers of methadone and its metabolite (2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine) in human plasma by enantioselective liquid chromatography with mass spectrometric detection. J Chromatogr A (2005) 0.79
A laboratory study of hydromorphone and cyclazocine on smoking behavior in residential polydrug users. Pharmacol Biochem Behav (2004) 0.78
Menstrual cycle length during methadone maintenance. Addiction (2005) 0.78
Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence. Am J Drug Alcohol Abuse (2002) 0.77
Daily temporal patterns of heroin and cocaine use and craving: relationship with business hours regardless of actual employment status. Addict Behav (2013) 0.77
Cardiac complications of unwitting co-injection of quinine/quinidine with heroin in an intravenous drug user. J Gen Intern Med (2012) 0.77
No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper. Am J Addict (2015) 0.77
Some of the people, some of the time: field evidence for associations and dissociations between stress and drug use. Psychopharmacology (Berl) (2015) 0.76
Effects of Prereactivation Propranolol on Cocaine Craving Elicited by Imagery Script/Cue Sets in Opioid-dependent Polydrug Users: A Randomized Study. J Addict Med (2015) 0.76
Aripiprazole for cocaine abstinence: a randomized-controlled trial with ecological momentary assessment. Behav Pharmacol (2016) 0.75
Perceptions of Neighborhood Mediate the Relationship Between PTSD Symptoms and Coping in a Neighborhood-Matched Substance-Using Sample. J Addict Med (2017) 0.75
Quantitative determination of the enantiomers of methadone and its metabolite (EDDP) in human saliva by enantioselective liquid chromatography with mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.75
Gender differences in indices of opioid dependency and medical comorbidity in a population of hospitalized HIV-infected African-Americans. Am J Addict (2004) 0.75
Clonidine Increases the Likelihood That Abstinence Can Withstand Unstructured Time in Buprenorphine-maintained Outpatients. J Addict Med (2017) 0.75